Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
77
FMS Quote, Financials, Valuation and Earnings
Last price:
$22.71
Seasonality move
:
1.91%
Day range:
$22.57 - $22.76
52-week range:
$17.93 - $24.31
Dividend yield:
2.83%
P/E ratio:
18.60x
P/S ratio:
0.64x
P/B ratio:
0.88x
Volume:
77.1K
Avg. volume:
267.8K
1-year change:
8.71%
Market cap:
$13.3B
Revenue:
$21.1B
EPS (TTM):
$1.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$5.4B | $0.38 | 9.89% | 20.05% | $20.96 |
|
AFMD
Affimed NV
|
$1.5M | -$1.06 | -50.03% | -42.4% | $18.90 |
|
BNTX
BioNTech SE
|
$561.1M | -$1.75 | -24.68% | -74.38% | $137.54 |
|
CVAC
CureVac NV
|
$150.6M | $1.54 | -66% | -69.73% | $7.38 |
|
IFRX
InflaRx NV
|
$84.1K | -$0.27 | 5602.11% | -2.23% | $8.04 |
|
IMTX
Immatics NV
|
$17.4M | -$0.28 | -5.77% | -3.64% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$22.71 | $20.96 | $13.3B | 18.60x | $0.64 | 2.83% | 0.64x |
|
AFMD
Affimed NV
|
$1.24 | $18.90 | $20.3M | -- | $0.00 | 0% | 20.08x |
|
BNTX
BioNTech SE
|
$114.13 | $137.54 | $27.4B | 184.86x | $0.00 | 0% | 8.34x |
|
CVAC
CureVac NV
|
$2.99 | $7.38 | $670.8M | 5.45x | $0.00 | 0% | 1.13x |
|
IFRX
InflaRx NV
|
$2.51 | $8.04 | $147.8M | -- | $0.00 | 0% | 800.79x |
|
IMTX
Immatics NV
|
$7.10 | -- | $863M | -- | $0.00 | 0% | 5.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
-- | 0.144 | -- | 0.78x |
|
AFMD
Affimed NV
|
31.93% | 0.815 | 16.35% | 1.76x |
|
BNTX
BioNTech SE
|
1.26% | 0.543 | 0.96% | 7.10x |
|
CVAC
CureVac NV
|
-- | 2.309 | -- | 6.10x |
|
IFRX
InflaRx NV
|
-- | 4.286 | -- | 4.34x |
|
IMTX
Immatics NV
|
-- | 1.740 | -- | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$1.3B | $464.1M | 3.22% | 4.37% | 10.08% | -- |
|
AFMD
Affimed NV
|
-- | -$15.7M | -127.62% | -158.94% | -9594.22% | -$13.2M |
|
BNTX
BioNTech SE
|
$1.2B | $11.5M | -2.32% | -2.35% | 13.39% | -$770.2M |
|
CVAC
CureVac NV
|
$519.1M | $404.1M | 21.3% | 21.3% | 75.06% | $381.2M |
|
IFRX
InflaRx NV
|
$216K | -$16.9M | -61.55% | -61.55% | -14084.63% | -$11.2M |
|
IMTX
Immatics NV
|
-- | $565.3K | -16.88% | -16.88% | -4.19% | -$42M |
Fresenius Medical Care AG vs. Competitors
-
Which has Higher Returns FMS or AFMD?
Affimed NV has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of -9767.12%. Fresenius Medical Care AG's return on equity of 4.37% beat Affimed NV's return on equity of -158.94%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG24.08% $0.40 $15.2B AFMDAffimed NV-- -$1.03 $28.2M -
What do Analysts Say About FMS or AFMD?
Fresenius Medical Care AG has a consensus price target of $20.96, signalling upside risk potential of 3.39%. On the other hand Affimed NV has an analysts' consensus of $18.90 which suggests that it could grow by 1421.72%. Given that Affimed NV has higher upside potential than Fresenius Medical Care AG, analysts believe Affimed NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG0 2 1 AFMDAffimed NV5 1 0 -
Is FMS or AFMD More Risky?
Fresenius Medical Care AG has a beta of 0.939, which suggesting that the stock is 6.093% less volatile than S&P 500. In comparison Affimed NV has a beta of 2.063, suggesting its more volatile than the S&P 500 by 106.315%.
-
Which is a Better Dividend Stock FMS or AFMD?
Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.83%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or AFMD?
Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than Affimed NV quarterly revenues of $170.5K. Fresenius Medical Care AG's net income of $234.3M is higher than Affimed NV's net income of -$16.7M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.60x while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.64x versus 20.08x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.64x 18.60x $5.2B $234.3M AFMDAffimed NV20.08x -- $170.5K -$16.7M
-
Which has Higher Returns FMS or BNTX?
BioNTech SE has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of 15.91%. Fresenius Medical Care AG's return on equity of 4.37% beat BioNTech SE's return on equity of -2.35%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG24.08% $0.40 $15.2B BNTXBioNTech SE85.63% $0.89 $21.6B -
What do Analysts Say About FMS or BNTX?
Fresenius Medical Care AG has a consensus price target of $20.96, signalling upside risk potential of 3.39%. On the other hand BioNTech SE has an analysts' consensus of $137.54 which suggests that it could grow by 20.51%. Given that BioNTech SE has higher upside potential than Fresenius Medical Care AG, analysts believe BioNTech SE is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG0 2 1 BNTXBioNTech SE11 5 0 -
Is FMS or BNTX More Risky?
Fresenius Medical Care AG has a beta of 0.939, which suggesting that the stock is 6.093% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.349%.
-
Which is a Better Dividend Stock FMS or BNTX?
Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.83%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or BNTX?
Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than BioNTech SE quarterly revenues of $1.4B. Fresenius Medical Care AG's net income of $234.3M is higher than BioNTech SE's net income of $217.9M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.60x while BioNTech SE's PE ratio is 184.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.64x versus 8.34x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.64x 18.60x $5.2B $234.3M BNTXBioNTech SE8.34x 184.86x $1.4B $217.9M
-
Which has Higher Returns FMS or CVAC?
CureVac NV has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of 68.44%. Fresenius Medical Care AG's return on equity of 4.37% beat CureVac NV's return on equity of 21.3%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG24.08% $0.40 $15.2B CVACCureVac NV95.56% $1.65 $809.4M -
What do Analysts Say About FMS or CVAC?
Fresenius Medical Care AG has a consensus price target of $20.96, signalling upside risk potential of 3.39%. On the other hand CureVac NV has an analysts' consensus of $7.38 which suggests that it could grow by 144.29%. Given that CureVac NV has higher upside potential than Fresenius Medical Care AG, analysts believe CureVac NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG0 2 1 CVACCureVac NV3 4 0 -
Is FMS or CVAC More Risky?
Fresenius Medical Care AG has a beta of 0.939, which suggesting that the stock is 6.093% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock FMS or CVAC?
Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.83%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or CVAC?
Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than CureVac NV quarterly revenues of $543.2M. Fresenius Medical Care AG's net income of $234.3M is lower than CureVac NV's net income of $371.8M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.60x while CureVac NV's PE ratio is 5.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.64x versus 1.13x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.64x 18.60x $5.2B $234.3M CVACCureVac NV1.13x 5.45x $543.2M $371.8M
-
Which has Higher Returns FMS or IFRX?
InflaRx NV has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of -14092.9%. Fresenius Medical Care AG's return on equity of 4.37% beat InflaRx NV's return on equity of -61.55%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG24.08% $0.40 $15.2B IFRXInflaRx NV-5376.61% -$0.33 $72.9M -
What do Analysts Say About FMS or IFRX?
Fresenius Medical Care AG has a consensus price target of $20.96, signalling upside risk potential of 3.39%. On the other hand InflaRx NV has an analysts' consensus of $8.04 which suggests that it could grow by 220.48%. Given that InflaRx NV has higher upside potential than Fresenius Medical Care AG, analysts believe InflaRx NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG0 2 1 IFRXInflaRx NV3 1 0 -
Is FMS or IFRX More Risky?
Fresenius Medical Care AG has a beta of 0.939, which suggesting that the stock is 6.093% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.534%.
-
Which is a Better Dividend Stock FMS or IFRX?
Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.83%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or IFRX?
Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than InflaRx NV quarterly revenues of $136.2K. Fresenius Medical Care AG's net income of $234.3M is higher than InflaRx NV's net income of -$19.2M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.60x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.64x versus 800.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.64x 18.60x $5.2B $234.3M IFRXInflaRx NV800.79x -- $136.2K -$19.2M
-
Which has Higher Returns FMS or IMTX?
Immatics NV has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of -16.95%. Fresenius Medical Care AG's return on equity of 4.37% beat Immatics NV's return on equity of -16.88%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG24.08% $0.40 $15.2B IMTXImmatics NV-- -$0.12 $427.2M -
What do Analysts Say About FMS or IMTX?
Fresenius Medical Care AG has a consensus price target of $20.96, signalling upside risk potential of 3.39%. On the other hand Immatics NV has an analysts' consensus of -- which suggests that it could grow by 135.92%. Given that Immatics NV has higher upside potential than Fresenius Medical Care AG, analysts believe Immatics NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG0 2 1 IMTXImmatics NV6 0 0 -
Is FMS or IMTX More Risky?
Fresenius Medical Care AG has a beta of 0.939, which suggesting that the stock is 6.093% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.688%.
-
Which is a Better Dividend Stock FMS or IMTX?
Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.83%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or IMTX?
Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than Immatics NV quarterly revenues of $55.6M. Fresenius Medical Care AG's net income of $234.3M is higher than Immatics NV's net income of -$9.4M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.60x while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.64x versus 5.70x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.64x 18.60x $5.2B $234.3M IMTXImmatics NV5.70x -- $55.6M -$9.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
